Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In a phase III trial, the addition of glucocorticoids to standard therapy did not prevent the development of coronary artery lesions in children with Kawasaki disease.
Positive results of the phase III VALOR trial suggest that the TYK2–JAK1 inhibitor brepocitinib is safe and effective for the treatment of dermatomyositis.
In mice with early-onset disc degeneration, treatment with dasatinib and quercetin suppressed senescence-associated signalling and preserved disc cell phenotype.
In the placebo-controlled phase III ALLEGORY trial, treatment with obinutuzumab reduced disease activity in adults with systemic lupus erythematosus over 52 weeks.
A multi-omics study reveals that lactylation of the antioxidant enzyme SOD1 promotes oxidative stress and intervertibral disc degeneration. Blocking this modification, genetically or with a targeted inhibitor, reduced oxidative damage and alleviated disc degeneration in rat models of IVDD.
Findings suggest that changes in serum IgG4 levels over time are predictive of IgG4-related disease relapse and might identify patients amenable to preventative treatment.
Two studies highlight the potential of inhibiting the transcription factor SIX1 or its downstream mediator plasminogen activator inhibitor 1 as a strategy to limit fibrosis in systemic sclerosis.
Drawing on my contrasting experiences as a patient in oncology and rheumatology, I have seen how the lack of precision-based diagnostics and meaningful endpoints limits progress in rheumatic disease. I believe biologically grounded classification systems and greater patient involvement are essential for more effective and responsive care.
The emergence of potent depletion therapies for the treatment of refractory autoimmunity has led to the concept of immune reset. Understanding whether immune reset equates to cure, and whether cure is achievable through non-depleting approaches, depends on the identification of immune biomarkers for measuring healthy and pathological immunity.
The findings of the pivotal RESET-RA trial demonstrate the clinical benefits and safety of an implanted neuromodulation device that stimulates the vagus nerve for the treatment of rheumatoid arthritis.
Comparing dermatomyositis with cutaneous lupus erythematosus, single-cell analysis identifies monocyte-mediated endothelial injury as a dermatomyositis-specific feature and highlights JAK1 inhibition as a potential therapeutic approach.
An erythrocyte-based strategy to achieve durable immunotolerance prevents the formation of neutralizing antibodies against uricase and facilitates urate clearance in animal models of gout.
A new study reveals that the Epstein–Barr virus can reprogramme autoreactive B cells into pathogenic antigen-presenting cells in systemic lupus erythematosus, providing a mechanistic link between infection and autoimmunity.
Autologous haematopoietic stem cell transplantation revolutionized the treatment of severe systemic sclerosis as the first therapy able to induce long-term remission in this relentlessly fibrosing disease. Nevertheless, questions remain about patient selection, conditioning, and how this treatment fits into the evolving immune-modifying therapeutic landscape. The field should move beyond standardization towards precision therapy.
